A Review of Second-Generation Antipsychotic Discontinuation in First-Episode Psychosis
- 1 September 2008
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Psychiatric Practice
- Vol. 14 (5) , 289-300
Abstract
"All-causes discontinuation" refers to discontinuation of treatment for any reason, and adherence to medication is an important component of this measure. Two recent landmark studies suggest that adherence is a major issue in patients with first-episode psychosis (FEP) right from the onset of treatment. In this review, the incidence, reasons for, and clinical outcomes of medication discontinuation in FEP are considered. More than 40% of patients with FEP discontinue medication during the first 9 months of treatment, at which point the chances of relapse increase dramatically. Findings concerning predictors of medication discontinuation in this patient population that have been replicated in more than one study include severity of psychopathology, lack of insight into illness, negative attitudes towards medications, comorbid substance use, and medication side effects. Interventions that have the potential to decrease discontinuation rates in patients with psychotic disorders include orally disintegrating tablets, long-acting injectable drugs, cognitive-behavioral therapy, compliance therapy, family support/intervention, and peer support, although these strategies have largely been unexplored in FEP. In addition to the question of medication discontinuation in the acute treatment of FEP, another important issue is how long patients with FEP should be treated with antipsychotics once they have achieved remission; unfortunately, little evidence is available to guide the decision as to whether medication should be discontinued or maintenance treatment provided in this situation. Studies are therefore needed to identify predictors of patients with remitted FEP who are less likely to relapse when medication is discontinued. Taken together, the findings presented in this article underscore the importance of addressing issues related to medication discontinuation as a means of preventing long-term morbidity and enhancing remission and functional recovery in FEP.Keywords
This publication has 69 references indexed in Scilit:
- Long-Acting Injectable Risperidone in the Treatment of Subjects With Recent-Onset PsychosisJournal of Clinical Psychopharmacology, 2008
- Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trialThe Lancet, 2008
- Predictors of Antipsychotic-Induced Weight Gain in First-Episode PsychosisJournal of Clinical Psychopharmacology, 2008
- Predictors of Treatment Discontinuation and Medication Nonadherence in Patients Recovering From a First Episode of Schizophrenia, Schizophreniform Disorder, or Schizoaffective DisorderThe Journal of Clinical Psychiatry, 2008
- Guided Discontinuation Versus Maintenance Treatment in Remitted First-Episode PsychosisThe Journal of Clinical Psychiatry, 2007
- Insight in first-episode psychosisPsychological Medicine, 2006
- Towards consensus in the long-term management of relapse prevention in schizophreniaHuman Psychopharmacology: Clinical and Experimental, 2005
- Randomised controlled trial of compliance therapyThe British Journal of Psychiatry, 1998
- Determinants of Medication Compliance in Schizophrenia: Empirical and Clinical FindingsSchizophrenia Bulletin, 1997
- The Scottish first episode schizophrenia studyActa Psychiatrica Scandinavica, 1989